NTRA at a glance
Natera Inc (NTRA, SEC CIK 1604821) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Natera Inc (NTRA) reported revenue of $2.3 billion (up 35.9% from FY2024) and a net loss of $208.2 million. Diluted EPS was -$1.52.
- As of June 30, 2026, 41 institutional investment managers tracked by SignalX reported holding Natera Inc (NTRA) shares worth $19.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Chapman Steven Leonard on October 1, 2026 of 1,273 shares at $413.31 per share.
- In the last 90 days, NTRA insiders reported 0 open-market purchases ($0) and 127 open-market sales ($85.7M) on Form 4, a net sale of $85.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.3B
- +35.9% vs prior year
- Insiders · 90 days
- 0 buys · 127 sells
- Net −$85.7M
- 13F holders
- 41 funds
- $19.1B · +1 vs prior quarter
- Latest 10-Q
- Aug 7, 2026
- Quarterly report
SignalX for NTRA
Don't miss the next NTRA filing
- Alerts as it files. A push when NTRA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NTRA, by share count.
- Ask anything. An AI agent that reads every NTRA filing and answers with sources.
NTRA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Chapman Steven Leonard | Sell | Oct 1, 2026 | 1,273 | $413.31 |
| Moshkevich Solomon | Sell | Oct 1, 2026 | 200 | $411.62 |
| Moshkevich Solomon | Sell | Oct 1, 2026 | 954 | $413.11 |
| Moshkevich Solomon | Sell | Oct 1, 2026 | 1,846 | $415.07 |
| Sheena Jonathan | Sell | Sep 23, 2026 | 400 | $385.10 |
| Sheena Jonathan | Sell | Sep 23, 2026 | 2,175 | $386.71 |
| Sheena Jonathan | Sell | Sep 23, 2026 | 2,734 | $387.65 |
| Sheena Jonathan | Sell | Sep 23, 2026 | 1,293 | $388.71 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.7B | $2.3B |
| Operating Income | - | -$222.3M | -$309.9M |
| Net Income | -$434.8M | -$190.4M | -$208.2M |
| Op. Margin | - | -13.1% | -13.4% |
| Net Margin | - | -11.2% | -9.0% |
| Balance Sheet | |||
| Total Assets | - | $1.7B | $2.4B |
| Equity | $765.3M | $1.2B | $1.7B |
| ROE | -56.8% | -15.9% | -12.2% |
| Per Share | |||
| EPS | - | $-1.53 | $-1.52 |
| Cash Flow | |||
| Operating CF | -$247.0M | $135.7M | $215.3M |
| CapEx | $39.2M | $66.4M | $106.2M |
Source: XBRL data in Natera Inc (NTRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NTRA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 41 | $19.08B |
| Q1 2026 | 40 | $13.43B |
| Q4 2025 | 38 | $14.73B |
| Q3 2025 | 37 | $12.77B |
| Q2 2025 | 35 | $11.46B |
| Q1 2025 | 32 | $5.92B |
| Q4 2024 | 29 | $4.97B |
| Q3 2024 | 26 | $2.49B |
- FMR LLC (Fidelity)+2.90M (+113%)
- Goldman Sachs Group+952.9K (+124%)
- D.E. Shaw & Co+787.9K (+160%)
- Franklin Resources+240.6K (+10%)
- State Street Corp+238.1K (+7%)
- T. Rowe Price Group−3.16M (-26%)
- JPMorgan Chase & Co−521.3K (-4%)
- Invesco Ltd−385.0K (-31%)
- BNY Mellon−119.8K (-18%)
- Morgan Stanley−80.0K (-6%)
- Renaissance Technologies LLC−197.5K
- Blackstone Group−1.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 278 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NTRA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
NTRA SEC filings: frequently asked questions
Are NTRA insiders buying or selling?
In the last 90 days, Natera Inc (NTRA) officers, directors and 10% owners reported no open-market purchases and 127 open-market sales worth $85.7 million by 8 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NTRA stock?
As of June 30, 2026, the largest Natera Inc (NTRA) holders among the 13F filers tracked by SignalX were JPMorgan Chase & Co ($3.5 billion), BlackRock ($3.0 billion), T. Rowe Price Group ($2.4 billion), Vanguard Capital Management LLC ($1.7 billion), Vanguard Portfolio Management LLC ($1.6 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NTRA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Natera Inc (NTRA) reported revenue of $2.3 billion (up 35.9% from FY2024) and a net loss of $208.2 million. Diluted EPS was -$1.52. The figures come from the XBRL data in the 10-K.
What are the latest NTRA SEC filings?
Natera Inc (NTRA) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on October 2, 2026.
What is NTRA's SEC CIK number?
Natera Inc (NTRA)'s SEC Central Index Key (CIK) is 1604821. EDGAR lists every NTRA filing under that number.
Ask anything about NTRA
The research agent reads NTRA's filings, financials, insider trades and 13F holders, then answers with sources.